Diagnostics Is Becoming a Distributed-Sampling Infrastructure Business
One of the more revealing healthcare developments of the last forty-eight hours did not come from a trial readout or…
Category: Testing
Early Cancer Detection Is Becoming an Evidence-Compounding Business
The most interesting biotech development of the last forty-eight hours is not a Phase 3 success or a takeover bid.…
Precision Diagnostics Win When They Become Reimbursed Infrastructure
The most important biotech development of the last forty-eight hours is not a drug approval or another trial readout. It…
Oncology’s Next Edge May Be What Treatment Removes
The most consequential biotech development of the last forty-eight hours is not a flashy new target or another early-stage platform…
MEDIPOST Advances Regenerative Orthopedics with Phase III Trial for Knee Osteoarthritis
The landscape of regenerative medicine reached a significant milestone this week as MEDIPOST Inc. announced the treatment of the first U.S.…
Precision Medicine Still Runs on Unforgiving Proof Thresholds
Biotech investors often reserve their emotional energy for glamorous failures: breakthrough drugs that miss endpoints, gene-editing platforms that stumble, cell…
Precision Oncology Is Becoming a Diagnostics Discipline
A good deal of biotech storytelling still assumes that the decisive event is the drug itself: the molecule works, the…
Oncology Is Turning Maintenance Therapy Into Strategy
Drug development stories are often told through breakthroughs at the moment of diagnosis: a new target, a sharper biomarker, a…
The Liquid Biopsy Reality Check: Navigating the Promise and Limits of Blood-Based Cancer Detection
As multi-cancer early detection tests generate immense excitement, oncologists emphasize the need for rigorous clinical validation and temper expectations regarding…